# Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

> **NCT02768805** · PHASE2 · COMPLETED · sponsor: **Medicago** · enrollment: 900 (actual)

## Conditions studied

- Virus Diseases
- RNA Virus Infections
- Respiratory Tract Diseases
- Respiratory Tract Infections

## Interventions

- **BIOLOGICAL:** 15 µg/strain of Quadrivalent VLP Vaccine
- **BIOLOGICAL:** 30 µg/strain of Quadrivalent VLP Vaccine
- **BIOLOGICAL:** 15 µg/strain of the licensed quadrivalent vaccine

## Key facts

- **NCT ID:** NCT02768805
- **Lead sponsor:** Medicago
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-02
- **Primary completion:** 2016-05-17
- **Final completion:** 2016-11-26
- **Target enrollment:** 900 (ACTUAL)
- **Last updated:** 2020-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02768805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02768805, "Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02768805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*